Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
Crovalimab (anti-Complement C5) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab (anti-Complement C5) binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab (anti-Complement C5) can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab (anti-Complement C5) inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab (anti-Complement C5) has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research.
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg
| エンドトキシン濃度 | <1.0 EU/mg |
|---|---|
| ターゲット | C5 |
| アクセス番号 | P01031 |
| 同義語 | Anaphylatoxin C5a analog antibody | C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4 antibody | C5 antibody | C5a anaphylatoxin antibody | C5a antibody | C5b antibody | CO5_HUMAN antibody | Complement C5 alpha'' chain antibody | Complemen |
| 仕様と純度 | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| 特異性 | C5 |
| アイソタイプ | Human IgG1 |
| ライトチェーン・タイプ | kappa |
| SDS-PAGE | 26.4 kDa (Light Chain) & 52.7 kDa (Heavy Chain), under reducing conditions; 190.6 kDa, under non-reducing conditions. |
| 精製方法 | Protein A purified |
| 集中 | See COA |
| CAS | 1917321-26-6 |
| Product Description | Crovalimab (anti-Complement C5) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab (anti-Complement C5) binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab (anti-Complement C5) can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab (anti-Complement C5) inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab (anti-Complement C5) has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research. |
| 形状 | Liquid |
| 保管条件 | Store at -80°C,Avoid repeated freezing and thawing |
| 入荷 | Dry ice packs + Cold packs |
| 安定性と保管 | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
開始 $133.90
